Primed for resistance
Authors:
- 29 February 2012
- journal article
- Published by Springer Nature in Nature
- Vol. 483 (7387) , 44-45
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature, 2012
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsJournal of Clinical Oncology, 2012
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsNew England Journal of Medicine, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerProceedings of the National Academy of Sciences, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008